274 related articles for article (PubMed ID: 23496665)
1. Prostate cancer vaccines.
Michael A; Relph K; Annels N; Pandha H
Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
[TBL] [Abstract][Full Text] [Related]
2. New treatments for metastic prostate cancer.
Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
Buonerba C; Ferro M; Di Lorenzo G
Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
[TBL] [Abstract][Full Text] [Related]
5. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
Bulloch MN; Elayan MM; Renfroe HR
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
7. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
Paller CJ; Antonarakis ES
Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T: Prototype for development of anti-tumor vaccines.
Carballido E; Fishman M
Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538
[TBL] [Abstract][Full Text] [Related]
12. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
13. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
15. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.
Arlen PM; Wood LV
Expert Rev Vaccines; 2012 Mar; 11(3):287-302. PubMed ID: 22380822
[TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T for the treatment of advanced prostate cancer.
Frohlich MW
Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
[TBL] [Abstract][Full Text] [Related]
20. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]